The development of modern medicine in the 21st century can greatly contribute to better and more effective treating of many diseases. However, what’s is equally important for all diseases is – to be discovered in time. At a time when technology contributes to medicine and healthcare, it is easier to respond better to all the health challenges than it was before. This fact is of major importance, especially if we keep in mind the rising number of malignant cancer or related diseases. Today, modern methods in diagnostics have become the standard and medical services in this domain are far more accessible than they were before. In terms of technological and medical innovations, the last decade has made a big step forward, so today some diseases are treated almost routinely.
In spite of the fact that we live in an era of information, we can not be proud of great knowledge in certain areas. It can even be said that, in some issues, we are still very poorly informed. One of these topics is the problem of pelvic floor disease in women.
For this exact reason, education on these issues is a topic of great magnitude.
The Significant Work Of Renovia Inc.
The company Renovia Inc., headed by Marc Beer CEO, has focused its efforts on solving problems related to pelvic floor disorders in women.
The company located in Boston deals with medical and technological development and has recently been working intensively on developing diagnostic performances. Their focus is on therapeutic improvement in cases of urinary incontinence and pelvic floor disorders. This disorder that can lead to serious health complications, affects more than 250 million women around the globe.
Partners And Investors Of Renovia In A Joint Mission
The first pioneering venture of Renovia was the LEVA device – approved officially in 2018 by the
FDA. After this major breakthrough in the market, Renovia became interesting to investors. Especially to those who are entering the domain of health care issues. One of such investors – Longwood Fund – has joined forces with two other companies: Ascension Ventures from Missouri and Perceptive Advisors from New York. Four new diagnostic devices will be technologically improved and invested in. That also includes the development of the new generation of LEVA devices.
Showing great satisfaction, Marc Beer the CEO of Renovia believes that this type of cooperation is of great importance primarily for the future benefit of the patients. As Beer claims, the investors share the same enthusiasm and vision as Renovia. They hope that together they will succeed in their mission – to make life easier for women who are suffering from this disease.
The joint research of Renovia and its partners is focused on the development and merging of innovative sensory technology and a new digital health platform. This combination will greatly help in the disease treatment, but also in understanding the pelvic floor disorder in women and thereby relieve the disorders caused by this disorder.
Nevertheless, the Renovia has not yet officially announced the new line of products for this purpose but is keeping that as a secret until the promotion. It remains for us to wait and see the results of joint work and investment. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer